Vivek Subbiah - Concepedia

Author

Vivek Subbiah

The University of Texas MD Anderson Cancer Center ORCID

Also Known As

Anthony V. Benedetto, Drilon, Alexander, GAMBACORTI PASSERINI, CARLO, Steven L. Fletcher, V Subbiah, V. Subbiah, V., Subbiah, VIVEK SUBBIAH, Vivek Subbiah, Vivek Subbiah, MD

1.4K

Publications

30.7K

Citations

H-Index

156

Concepts

All Affiliations

The University of Texas MD Anderson Cancer Center Massachusetts General Hospital Institut Gustave Roussy Memorial Sloan Kettering Cancer Center Sarah Cannon

About

Vivek Subbiah is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	41	118	9.2K
2	Health Sciences	18	30	2K
3	Engineering	2	2	286
4	Arts	1	1	19
5	Natural Sciences	1	1	236

Vivek Subbiah

301

Publications

24.1K

Citations

H-Index

Page 1

	Year	Citations
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study Nicole M. Kuderer, Toni K. Choueiri, Dimpy P. Shah, The Lancet EpidemiologyCancer EpidemiologyMedicineGlobal HealthEpidemiology Of Cancer	2020	1.8K
Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations David M. Hyman, Igor Puzanov, Vivek Subbiah, New England Journal of Medicine	2015	1.7K
Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic <i>BRAF</i> V600–Mutant Anaplastic Thyroid Cancer Vivek Subbiah, Robert J. Kreitman, Zev A. Wainberg, Journal of Clinical Oncology Trametinib TreatmentConclusion DabrafenibMedicineRadionuclide TherapyLocally Advanced	2017	848
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer Alexander Drilon, Geoffrey R. Oxnard, Daniel Shao-Weng Tan, New England Journal of Medicine	2020	810
Efficacy of Selpercatinib in <i>RET</i> -Altered Thyroid Cancers Lori J. Wirth, Eric J. Sherman, Bruce Robinson, New England Journal of Medicine	2020	731
Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial Vivek Subbiah, Ulrik Lassen, Élena Elez, The Lancet Oncology Surgical OncologyOncologyGastrointestinal OncologyBiliary CancerPathology	2020	489
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial José Trigo, Vivek Subbiah, Benjamin Besse, The Lancet Oncology Second-line TreatmentOncologyMetronomic TherapyClinical TrialsPathology	2020	433
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study Justin F. Gainor, Giuseppe Curigliano, Dong‐Wan Kim, The Lancet Oncology	2021	428
Selective RET kinase inhibition for patients with RET-altered cancers Vivek Subbiah, Vamsidhar Velcheti, Brian B. Tuch, Annals of Oncology	2018	422
Vemurafenib for <i>BRAF</i> V600–Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis Eli L. Diamond, Vivek Subbiah, A. Craig Lockhart, JAMA Oncology	2017	395

Page 1